[exclusive] inhalation anesthetics -- Market Research Report of fluoroalkanes

General anesthetics can be classified into inhalation anesthetics and intravenous anesthetics according to the administration route According to the drug intelligence data, the market scale of narcotic drugs in 2015 was 12.159 billion yuan, an increase of 6.4% year on year Inhaled anesthetics account for 25% of the market share, with an annual growth rate of about 15%; intravenous anesthetics have a larger market scale and a faster growth rate than inhaled anesthetics The reason is that intravenous anesthetics are drugs distributed to nerve tissues through intravenous injection, which have a faster anesthesia effect, do not need auxiliary equipment such as anesthesia machine, and have no environmental pollution, so they are widely used In this paper, the market situation of inhaled anesthetics in recent years and the situation of R & D registration are analyzed, and the market prospect of anesthetics is predicted Fluoroalkanes are a kind of drugs that can inhibit the function of central nervous system, temporarily eliminate consciousness, sensation and reflex, relax skeletal muscle, mainly used for anesthesia before surgery The main products on the market include sevoflurane, desflurane, isoflurane and enflurane According to 2016 sales data, general anesthetics account for about 3 / 4 of the market share of the anesthetics market, and local anesthetics account for about 1 / 4 of the market share of the anesthetics market The proportion of general anesthesia in Europe and America is more than 90% In China, the proportion of general anesthesia operation is about 70%, among which the proportion of tertiary hospitals is about 70%, and the proportion of secondary and lower hospitals is only 20-30% Figure 1 proportion of anesthetics by category in 2016 Figure 2 proportion of inhaled anesthetics and intravenous anesthetics in 2016 market capacity and listing (1) domestic market figure 3 sales volume of inhaled anesthetics in sample hospitals in 2010-2015 Figure 4 sales volume of inhaled anesthetics in sample hospitals in 2015 according to PDB data, sales volume of sevoflurane in sample hospitals in 2015 was 4.72 Billion yuan, a year-on-year increase of 14.90%, sevoflurane accounted for 96.72% In the other three varieties, the sales of isoflurane decreased year by year from 22.3924 million yuan to 5.8506 million yuan in 2010-2015; the sales of enflurane also decreased from 3.3189 million yuan to 1.33 million yuan; in recent years, the performance of desflurane was excellent, the sales of sample hospitals in 2015 was 9.4983 million yuan, a year-on-year increase of 67.41%, and the three-year compound growth rate was 39.76% Figure 5 sales volume of heptafluorone in sample hospitals in 2015 Figure 6 sales volume of heptafluorone enterprises in sample hospitals in 2015, heptafluorone products Hengrui medicine accounted for more than half of the market share of the city's key hospitals, and the market share of Hengrui medicine in 2015 was 49.39% Total demand of sevoflurane in domestic market According to Hengrui's 2015 annual report, the sales volume of sevoflurane for inhalation in 2015 was 1055000 pieces Based on its market share of 49.39% in 2015, the total domestic market volume of sevoflurane in 2015 was about 2126000 pieces (each piece is 120ml according to Hengrui's specifications), and the total domestic demand of sevoflurane in 2015 was about 382.7t (212.6 * 104 * 120 * 1.5 * 10-6) (in addition, the sales volume of sevoflurane in Hengrui pharmaceutical in 2016 was 1.26 million pieces, because there was no such sales volume of 201 million pieces It is impossible to calculate the domestic market consumption of sevoflurane in 2016 due to the market share data of 6 years (2) The market size of inhaled anesthetics in the international market in 2015 is about US $1.23 billion, and the compound growth rate from 2016 to 2024 is estimated to be 3.5% The rapid growth of the elderly population, the incidence rate of chronic diseases including cardiovascular diseases, respiratory diseases, cancer and emergency surgery is the main factor in the growth of the market of inhalation anesthetics Table 1 - comparison data source of ceiling price and medical insurance of common inhalational anesthetic manufacturers: drug intelligence data, Soochow Securities Research Institute (Note: the notice on printing and distributing opinions on promoting drug price reform issued by the national development and Reform Commission in 2015 made it clear that except for narcotic drugs and class I psychotropic drugs including morphine and methadone, the national development and Reform Commission temporarily implemented the management of maximum ex factory price and maximum retail price, the government pricing of other drugs was cancelled and the management of maximum retail price limit was no longer implemented.) Figure 7 change of bidding price of sevoflurane of different manufacturers in this year table 2-comparison data source of physicochemical properties and efficacy of commonly used anesthetics: Anesthesiology, people's Health Press, Soochow Securities Research Institute table 3-listing data source of commonly used anesthetics: drug intelligence data, Soochow Securities Research Institute 2 Product market forecast There is still a certain market for inhaled general anesthesia drugs, and domestic drug manufacturers including Hengrui are also actively laying out the product pipeline in order to launch new products as soon as possible Sevoflurane: in 2015, it occupied most of the global market share of inhalation anesthesia, which may be attributed to its quantifiable advantages over other drugs Sevoflurane induced and recovered faster than other anesthetics In addition, it has low irritation and irritability caused by airway stimulation Desflurane: in 2015, the market value of desflurane reached US $280 million From 2016 to 2024, the compound growth rate expanded at a rate of 2.3% (this value includes the income from special vaporization device due to the special needs of the product) Baxte annual report shows in the data of sample hospitals in the United States (2014-2015), the dosage of each inhaled anesthetic is 13000 x 250 ml bottles of sevoflurane, 7000 x 240 ml bottles of desflurane (the original research of baxte is desflurane) and 260 x 250 ml bottles of isoflurane It can be seen that the proportion of sevoflurane is the largest in inhalation anesthetics Because of the need for special vaporization device, the promotion of the product is limited Isoflurane is gradually replaced by sevoflurane and desflurane Original statement: This article is the original manuscript of yaozhi.com, welcome to reprint, reprint please indicate the source and author, thank you!